- Home
- AMS vs BCTX Comparison
AMS vs BCTX Comparison
Compare AMS & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMS
- BCTX
- Stock Information
- Founded
- AMS 1980
- BCTX 2014
- Country
- AMS United States
- BCTX Canada
- Employees
- AMS N/A
- BCTX N/A
- Industry
- AMS Medical Specialities
- BCTX Biotechnology: Pharmaceutical Preparations
- Sector
- AMS Health Care
- BCTX Health Care
- Exchange
- AMS Nasdaq
- BCTX Nasdaq
- Market Cap
- AMS 17.2M
- BCTX 14.4M
- IPO Year
- AMS N/A
- BCTX N/A
- Fundamental
- Price
- AMS $2.51
- BCTX $7.72
- Analyst Decision
- AMS
- BCTX Strong Buy
- Analyst Count
- AMS 0
- BCTX 1
- Target Price
- AMS N/A
- BCTX $40.00
- AVG Volume (30 Days)
- AMS 4.0K
- BCTX 92.9K
- Earning Date
- AMS 08-13-2025
- BCTX 10-28-2025
- Dividend Yield
- AMS N/A
- BCTX N/A
- EPS Growth
- AMS N/A
- BCTX N/A
- EPS
- AMS N/A
- BCTX N/A
- Revenue
- AMS $29,251,000.00
- BCTX N/A
- Revenue This Year
- AMS $5.06
- BCTX N/A
- Revenue Next Year
- AMS N/A
- BCTX N/A
- P/E Ratio
- AMS N/A
- BCTX N/A
- Revenue Growth
- AMS 26.61
- BCTX N/A
- 52 Week Low
- AMS $2.27
- BCTX $6.00
- 52 Week High
- AMS $3.59
- BCTX $294.00
- Technical
- Relative Strength Index (RSI)
- AMS 51.57
- BCTX 40.75
- Support Level
- AMS $2.45
- BCTX $7.28
- Resistance Level
- AMS $2.53
- BCTX $8.82
- Average True Range (ATR)
- AMS 0.07
- BCTX 0.74
- MACD
- AMS 0.00
- BCTX 0.58
- Stochastic Oscillator
- AMS 36.67
- BCTX 60.82
About AMS American Shared Hospital Services
American Shared Hospital Services provides stereotactic radiosurgery equipment, Advanced radiation therapy, and related equipment. It currently provides Gamma Knife units to medical centers and stand-alone facilities. The company, along with its subsidiaries, operates through the following operations: Gamma Knife, Advanced Radiation Therapy Equipment and Services, and Proton Beam Radiation Therapy Operations. It generates most of its revenue from the domestic market.
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.